ES2437240B1 - Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón - Google Patents

Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón Download PDF

Info

Publication number
ES2437240B1
ES2437240B1 ES201230874A ES201230874A ES2437240B1 ES 2437240 B1 ES2437240 B1 ES 2437240B1 ES 201230874 A ES201230874 A ES 201230874A ES 201230874 A ES201230874 A ES 201230874A ES 2437240 B1 ES2437240 B1 ES 2437240B1
Authority
ES
Spain
Prior art keywords
copd
lung cancer
prognosis
diagnosis
classification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201230874A
Other languages
English (en)
Other versions
ES2437240A1 (es
Inventor
Luis Gonzalo PAZ-ARES GONZAGA
María Dolores PASTOR HERRERA
Sonia MOLINA PINELO
Amancio CARNERO MOYA
Ana SALINAS
Ana BARBOSA DE SOUZA NOGAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Servicio Andaluz de Salud
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Sevilla, Servicio Andaluz de Salud filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201230874A priority Critical patent/ES2437240B1/es
Priority to EP13800145.8A priority patent/EP2921858A4/en
Priority to US14/405,685 priority patent/US20150338422A1/en
Priority to PCT/ES2013/070364 priority patent/WO2013182725A1/es
Publication of ES2437240A1 publication Critical patent/ES2437240A1/es
Application granted granted Critical
Publication of ES2437240B1 publication Critical patent/ES2437240B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B21/00—Nitrogen; Compounds thereof
    • C01B21/082—Compounds containing nitrogen and non-metals and optionally metals
    • C01B21/087—Compounds containing nitrogen and non-metals and optionally metals containing one or more hydrogen atoms
    • C01B21/092—Compounds containing nitrogen and non-metals and optionally metals containing one or more hydrogen atoms containing also one or more metal atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón.#Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los individuos con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón en a) individuos sin EPOC ni cáncer de pulmón, b) individuos con EPOC, c) individuos con adenocarcinoma, d) individuos con EPOC y adenocarcinoma, o e) individuos con EPOC y carcinoma escamoso. La presente invención describe además un kit de diagnóstico, así como un dispositivo y sus usos para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón según se ha indicado anteriormente.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18

Claims (1)

  1. imagen1
    imagen2
ES201230874A 2012-06-05 2012-06-05 Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón Withdrawn - After Issue ES2437240B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201230874A ES2437240B1 (es) 2012-06-05 2012-06-05 Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón
EP13800145.8A EP2921858A4 (en) 2012-06-05 2013-06-05 METHOD OF OBTAINING DATA USEFUL FOR THE DIAGNOSIS, PROGNOSIS AND CLASSIFICATION OF PATIENTS WITH CHRONIC OBSTRUCTIVE BRONCHO PNEUMOPATHY (BCPO) AND / OR LUNG CANCER
US14/405,685 US20150338422A1 (en) 2012-06-05 2013-06-05 Method for obtaining data that are useful for the diagnosis, prognosis and classification of patients with chronic obstructive pulmonary disease (copd) and/or lung cancer
PCT/ES2013/070364 WO2013182725A1 (es) 2012-06-05 2013-06-05 Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (epoc) y/o cancer de pulmón

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230874A ES2437240B1 (es) 2012-06-05 2012-06-05 Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón

Publications (2)

Publication Number Publication Date
ES2437240A1 ES2437240A1 (es) 2014-01-09
ES2437240B1 true ES2437240B1 (es) 2014-10-16

Family

ID=49711455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230874A Withdrawn - After Issue ES2437240B1 (es) 2012-06-05 2012-06-05 Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón

Country Status (4)

Country Link
US (1) US20150338422A1 (es)
EP (1) EP2921858A4 (es)
ES (1) ES2437240B1 (es)
WO (1) WO2013182725A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112848A1 (en) * 2014-01-24 2015-07-30 National Jewish Health Methods for detection of respiratory diseases
CN111213058A (zh) * 2017-05-24 2020-05-29 格拉纳达大学 在外周血中循环的上皮细胞的分离
US20220003785A1 (en) * 2018-10-18 2022-01-06 Proterixbio, Inc. Methods for targeted assessment and treatment of chronic obstructive pulmonary disease and acute events and mortality associated therewith
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315218C (en) * 1997-12-16 2007-03-20 Teijin Limited Analysis of predisposition based on human airway tripsin protease gene polymorphism
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US8476420B2 (en) * 2007-12-05 2013-07-02 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells

Also Published As

Publication number Publication date
EP2921858A1 (en) 2015-09-23
EP2921858A4 (en) 2016-09-21
ES2437240A1 (es) 2014-01-09
WO2013182725A1 (es) 2013-12-12
US20150338422A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
ES2437240B1 (es) Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón
WO2015031694A3 (en) Oligonucleotide probes and uses thereof
DE112013003442A5 (de) Testkit (Kombi-Schnelltest) zum synchronen Nachweis von Biomarkern im Stuhl zur Erkennung pathologischer Veränderungen im Gastrointenstinaltrakt, insbesondere im Darm
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
Woolgar et al. Squamous cell carcinoma and precursor lesions: clinical pathology.
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
ES2524164B1 (es) Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
BR112015027249A2 (pt) método de diagnóstico de câncer
ES2493069T3 (es) CYBP como marcador del cáncer de pulmón
CA2863427A1 (en) Use of pdgfr-.alpha. as diagnostic marker for papillary thyroid cancer
WO2014143794A3 (en) Diagnostic and prognostic marker for prostate cancer
ES2523903B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
Kountouras et al. is Helicobacter pylori behind Barrett's oesophagus and colorectal neoplasms?
Xu et al. Disseminated actinomycosis
Printz Ultrasound better than mammography for women younger than 40 years with symptoms of breast cancer.
ES1135017U (es) Instrumento de medición para determinar un punto de medición anatómica
ES2482468A1 (es) Método de obtención de datos útiles para el diagnóstico diferencial del cáncer de pulmón
ES2495266B1 (es) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
Nakazuru et al. Gastrointestinal: Unusual duodenal follicular lymphoma observed by magnifying endoscopy with narrow-band imaging.
ES2461016B1 (es) Método para el diagnóstico y/o pronóstico de obesidad mórbida
ES2538597B1 (es) Dispositivo para la detección de Shigella dysenteriae serotipo 1
ES2526823B1 (es) Biomarcadores, método y kit para el diagnóstico temprano del adenocarcinoma ductal de páncreas
CH704790C1 (fr) Instrument d’écriture à pointe rétractable.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2437240

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141016

FA2A Application withdrawn

Effective date: 20150212